The Swiss maker of pharmaceuticals, surgical products and products to treat eye disorders, which is being taken over by Novartis, has reported global sales of $1,536.4 million for the first quarter, up by 16.2 percent over last year. Excluding foreign currency effects, this was an increase of 9.4 percent. Alcon ...
Buying a membership today will give you:
To continue reading this article register now.